Table 2.
Characteristics of and immune markers in patients with positive and negative programmed cell death ligand 1 (PD-L1) expression.
| Category | PD-L1 positive | PD-L1 negative | Total |
|---|---|---|---|
| Gender, n (%) | |||
| Female | 4 (44.4%) | 7 (31.8%) | 11 (35.5%) |
| Male | 5 (55.6%) | 15 (68.2%) | 20 (64.5%) |
| Median age at diagnosis (range) | 70 (46–80) | 60.5 (20–81) | 65 (20–81) |
| Primary sites, n (%) | |||
| Stomach | 8 (88.9%) | 12 (54.5%) | 20 (64.5%) |
| Pancreas | 1 (11.1%) | 5 (22.7%) | 6 (19.4%) |
| Other sites | 0 (0.0%) | 5 (22.7%) | 5 (16.1%) |
| Median Ki-67 index (range) | 80% (50–95) | 80% (30–90) | 80% (30–95) |
| TNM stage, n (%) | |||
| I | 1 (11.1%) | 1 (4.5%) | 2 (6.5%) |
| II | 3 (33.3%) | 9 (40.9%) | 12 (38.7%) |
| III | 5 (55.6%) | 9 (40.9%) | 14 (45.2%) |
| IV | 0 (0%) | 3 (13.6%) | 3 (9.7%) |
| CD3+ Cell infiltration, n (%) | |||
| High infiltration | 6 (66.7%) | 3 (13.6%) | 9 (29.0%) |
| Low infiltration | 3 (33.3%) | 19 (86.4%) | 22 (71.0%) |
| CD8+ cell infiltration, n (%) | |||
| Infiltration | 4 (44.4%) | 5 (22.7%) | 9 (29.0%) |
| No infiltration | 5 (55.6%) | 17 (77.3%) | 22 (71.0%) |
| CD68+ Cell infiltration, n (%) | |||
| High infiltration | 3 (33.3%) | 3 (13.6%) | 6 (19.4%) |
| Low infiltration | 6 (66.7%) | 19 (86.4%) | 25 (80.6%) |
| Median tumor mutation burden (range) | 6.58 (3.92–11.75) | 5.18 (0.57–11.33) | 5.915 (0.57–11.75) |